64CuATSM and Hypoxia in Stage IV Non-small Cell Lung Cancer With Carboplatin, Paclitaxel, and Bevacizumab
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine:
- Whether bevacizumab increases the amount of oxygen in cancer as measured by a special
positron emission tomography (PET) scan using 64Cu-ATSM.
- Whether the amount of oxygen in cancer as measured by 64Cu-ATSM PET scan predicts how
well the cancer responds to treatment with chemotherapy.